KAKKIS EMIL D (President & CEO) sold 7.6% of their position (54.40K shares) of ULTRAGENYX PHARMACEUTICAL INC. on the open market
Open‑market sale worth $1.24M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 3/3/2026ACC: 0001193125-26-089278
DirectorOfficer· President & CEO
Since Mar 2026
+16.77K
Net shares
Net buyer
$1.24M
Total sold
1
Open market trades
0B · 1S
2
Total transactions
71.18K acquired · 54.40K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+71.18K
Price / share
—
Trade value
—
% of position
11.1%
3/1/2026
641.73K→712.91K
Common Stock
Direct
Shares
−54.40K
Price / share
$22.80
Trade value
$1.24M
% of position
7.6%
3/2/2026
713.40K→658.99K
Total
Net shares
+16.77K
Net value
-$1.24M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/1/2026 | A · Award | +71.18K | — | — | 11.1% | 641.73K | 712.91K |
| Common Stock Direct | 3/2/2026 | S · Sale | −54.40K | $22.80 | $1.24M | 7.6% | 713.40K | 658.99K |
| Total | +16.77K | -$1.24M | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned2.16M
Total
2.16M indirect2.16M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 2.16M | Indirect |
| Total | 2.16M | 2.16M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported